CD24Fc
Phase 3- Indications
- COVID-19, Graft versus host disease
Company intelligence / Profile preview
OncoImmune
Rockville, Maryland, United Statesoncoimmune.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
OncoImmune’s lead product, CD24Fc, demonstrated efficacy in a Phase 3 trial for severe/critical COVID‑19 patients—showing a significant improvement over placebo—and was also studied up to pivotal trials for GVHD prevention. The company also initiated first-in-human studies of ONC‑392, a novel anti–CTLA‑4 antibody designed to improve safety and efficacy over existing checkpoint inhibitors.
- Therapeutic areas
- OncologyHematologyInfectious Diseases
- Modalities
- Recombinant fusion proteinsMonoclonal antibodiesProtein therapeuticsSmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on OncoImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoImmune.